

Supplemental Online Content

Enevold C, Loft N, Bregnhøj A, et al. Circulating brodalumab levels and therapy outcomes in patients with psoriasis treated with brodalumab: a case series. *JAMA Dermatol*. Published online June 1, 2022. doi:10.1001/jamadermatol.2022.1863

eTable. Baseline Patient Characteristics

This supplemental material has been provided by the authors to give readers additional information about their work.

Table. Baseline Patient Characteristics

| Characteristic | No. (%) |
|--|--------------|
| No. | 20 |
| Women | 7 (35) |
| Men | 13 (65) |
| Age, median (range), y | 50 (19-66) |
| Body weight, median (range), kg | 103 (59-182) |
| BMI, median (range), kg/m ² | 32 (21-50) |
| Baseline PASI, median (range) | 14 (7-26) |
| Previous therapy failure | |
| Secukinumab-only | 14 (70) |
| Ixezumab-only | 1 (5) |
| Secukinumab and ixekizumab | 5 (25) |
| TNF-alpha inhibitor (adalimumab, infliximab, or etanercept) | 16 (80) |
| IL-12/IL-23 inhibitor (ustekinumab, guselkumab) | 12 (60) |
| TNF-alpha or IL-12/IL-23 inhibitor | 18 (90) |
| Previous therapy failures on other biologics or small molecules, median (range), No. | 2 (0-6) |

Abbreviations: BMI, body mass index; IL, interleukin; PASI, psoriasis area and severity indexes; TNF, tumor necrosis factor.